How does continuous venovenous hemofiltration theoretically expose (ex-vivo models) inpatients to diethylhexyladipate, a plasticizer of PVC medical devices?
- 17 February 2020
- journal article
- research article
- Published by Elsevier BV in Chemosphere
- Vol. 250, 126241
- https://doi.org/10.1016/j.chemosphere.2020.126241
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Bisphenol A in Chronic Kidney DiseaseArtificial Organs, 2012
- Effects of plasticizers and their mixtures on estrogen receptor and thyroid hormone functionsToxicology Letters, 2009
- Accumulation of Bisphenol A in Hemodialysis PatientsBlood Purification, 2007
- The Estrogenic Effect of Bisphenol A Disrupts Pancreatic β-Cell Function In Vivo and Induces Insulin ResistanceEnvironmental Health Perspectives, 2006
- Risk assessment of di(2-ethylhexyl)phthalate released from PVC blood circuits during hemodialysis and pump–oxygenation therapyInternational Journal of Pharmaceutics, 2004
- Steroidogenesis in fetal male rats is reduced by DEHP and DINP, but endocrine effects of DEHP are not modulated by DEHA in fetal, prepubertal and adult male ratsReproductive Toxicology, 2004
- Kinetics of diethylhexyl‐phthalate extraction From polyvinylchloride‐infusion linesJournal of Parenteral and Enteral Nutrition, 2002
- Determination of the endocrine disrupter bisphenol—A in the blood of uremia patients treated by dialysisChromatographia, 2001
- Circulating concentrations of di(2-ethylhexyl) phthalate and its de-esterified phthalic acid products following plasticizer exposure in patients receiving hemodialysisToxicology and Applied Pharmacology, 1985
- The release of plasticizer from polyvinyl chloride haemodialysis tubingJournal of Pharmacy and Pharmacology, 1977